Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $1.86 in the prior trading day, Emergent Biosolutions Inc (NYSE: EBS) closed at $2.04, up 9.68%. In other words, the price has increased by $9.68 from its previous closing price. On the day, 0.94 million shares were traded. EBS stock price reached its highest trading level at $2.06 during the session, while it also had its lowest trading level at $1.84.
Ratios:
Our goal is to gain a better understanding of EBS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.54 and its Current Ratio is at 1.04. In the meantime, Its Debt-to-Equity ratio is 1.35 whereas as Long-Term Debt/Eq ratio is at 0.71.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 02 ’23 when Zoon Kathryn C sold 1,830 shares for $8.35 per share. The transaction valued at 15,280 led to the insider holds 49,971 shares of the business.
Zoon Kathryn C sold 1,700 shares of EBS for $14,246 on May 25 ’23. The Director now owns 51,801 shares after completing the transaction at $8.38 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EBS now has a Market Capitalization of 106877232 and an Enterprise Value of 872294976. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.10 while its Price-to-Book (P/B) ratio in mrq is 0.16. Its current Enterprise Value per Revenue stands at 0.831 whereas that against EBITDA is -12.338.
Stock Price History:
The Beta on a monthly basis for EBS is 1.22, which has changed by -0.79881656 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, EBS has reached a high of $10.92, while it has fallen to a 52-week low of $1.42. The 50-Day Moving Average of the stock is -14.15%, while the 200-Day Moving Average is calculated to be -37.93%.
Shares Statistics:
The stock has traded on average 2.99M shares per day over the past 3-months and 928910 shares per day over the last 10 days, according to various share statistics. A total of 52.20M shares are outstanding, with a floating share count of 50.09M. Insiders hold about 4.05% of the company’s shares, while institutions hold 78.02% stake in the company. Shares short for EBS as of 1711584000 were 5702358 with a Short Ratio of 1.91, compared to 1709164800 on 6202003. Therefore, it implies a Short% of Shares Outstanding of 5702358 and a Short% of Float of 18.020001.
Earnings Estimates
Emergent Biosolutions Inc (EBS) is presently subject to a detailed evaluation by 1 analysts, each offering their unique perspectives on its market standing.On average, analysts expect EPS of -$0.83 for the current quarter, with a high estimate of -$0.83 and a low estimate of -$0.83, while EPS last year was -$3.17. The consensus estimate for the next quarter is -$0.63, with high estimates of -$0.63 and low estimates of -$0.63.
Analysts are recommending an EPS of between -$2 and -$2 for the fiscal current year, implying an average EPS of -$2. EPS for the following year is $3.67, with 1 analysts recommending between $3.67 and $3.67.
Revenue Estimates
A total of 1 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $1.02B, while the lowest revenue estimate was $1.02B, resulting in an average revenue estimate of $1.02B. In the same quarter a year ago, actual revenue was $1.05B, down -2.30% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $1.13B in the next fiscal year. The high estimate is $1.13B and the low estimate is $1.13B. The average revenue growth estimate for next year is up 9.90% from the average revenue estimate for this year.
